title: Management of locally advanced and metastatic colon cancer in elderly patients.
abstract: Colon cancer is the second leading cause of cancer mortality in the United States with a median age at diagnosis of 69 years. Sixty percent are diagnosed over the age of 65 years and 36% are 75 years or older. At diagnosis, approximately 58% of patients will have locally advanced and metastatic disease, for which systemic chemotherapy has been shown to improve survival. Treatment of cancer in elderly patients is more challenging due to multiple factors, including disabling co-morbidities as well as a decline in organ function. Cancer treatment of elderly patients is often associated with more toxicities that may lead to frequent hospitalizations. In locally advanced disease, fewer older patients receive adjuvant chemotherapy despite survival benefit and similar toxicity when compared to their younger counterparts. A survival benefit is also observed in the palliative chemotherapy setting for elderly patients with metastatic disease. When treating elderly patients with colon cancer, one has to consider drug pharmacokinetics and pharmacodynamics. Since chronological age is a poor marker of a patient's functional status, several methods of functional assessment including performance status and activities of daily living (ADL) or instrumental ADL, or even a comprehensive geriatric assessment, may be used. There is no ideal chemotherapy regimen that fits all elderly patients and so a regimen needs to be tailored for each individual. Important considerations when treating elderly patients include convenience and tolerability. This review will discuss approaches to the management of elderly patients with locally advanced and metastatic colon cancer.
authors.affiliation: Peter C Kurniali, Borys Hrinczenko, Anas Al-Janadi, Division of Hematology/Oncology, Michigan State University, MI 48910, United States.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Kurniali
authors.affiliation: Peter C Kurniali, Borys Hrinczenko, Anas Al-Janadi, Division of Hematology/Oncology, Michigan State University, MI 48910, United States.
authors.forename: Borys
authors.initials: B
authors.lastname: Hrinczenko
authors.affiliation: Peter C Kurniali, Borys Hrinczenko, Anas Al-Janadi, Division of Hematology/Oncology, Michigan State University, MI 48910, United States.
authors.forename: Anas
authors.initials: A
authors.lastname: Al-Janadi
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000453:epidemiology / Q000628:therapy*; D015897:Comorbidity; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010166:Palliative Care / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
keywords: Chemotherapy; Colon cancer; Elderly; Management; Toxicity